Abstract
Nerve growth factor plays an important role in the transmission of information from the site of injury to the brain. It is a neurotrophin that modulates pain and tenderness, which is produced by various cell types and at the same time its production is induced by proinflammatory cytokines.
Tanezumab is a humanized monoclonal antibody that selectively binds to excess nerve growth factor, thereby blocking pain transmission. The effect was demonstrated in the preclinical phase in models for pain associated with osteoarthritis, lumbar spine pain and cancer pain.
The article introduces the results of recent clinical trials conducted following the revocation of the temporary suspension of clinical research by the US Food and Drug Administration. Following the resumption of clinical trials, intravenous tanezumab was changed to subcutaneous, the indication was targeted to patients with failure of standard analgesic medication, and joint safety was rigorously evaluated in all studies.